Angiogenesis is defined as the growth of blood vessels from preexisting microvasculature. Therapeutic angiogenesis seeks to employ this phenomenon to treat patients with inadequate tissue perfusion by inducing neovascular growth. The goals of this project are: to develop anatomically-, biophysically-, and physiologically-detailed integrative multi-scale computational models of angiogenesis in normal and diseased skeletal muscle; to use highly synergistic and interactive computational and experimental approaches to understand physiologic and pathologic adaptations in mouse and human muscle; and to design improved and novel human therapeutics. Specifically, the experimentally-validated computational models will be used to understand, design and optimize therapies for human peripheral arterial obstructive disease (PAOD), a major cause of amputation and death. Currently there are no medical therapies available for PAOD that have the ability to increase perfusion and correct the principal abnormality of impaired blood flow. The vascular endothelial growth factor (VEGF) family of ligands and receptors will serve as the core focus of this project. To synthesize computational and experimental approaches, a collaboration has been established between computational biologists/bioengineers from Johns Hopkins University and basic/translational scientists from Duke University School of Medicine. Experimental data will be obtained from tissues of the normal and diabetic mouse and human with and without PAOD and the results will be utilized in multi-scale computational models, spanning from the molecule, to the tissue, to the organism level. The iteration of computational and experimental approaches will permit unparalleled investigation in the highly significant field of angiogenesis. This inter-disciplinary approach will have an immediate impact on fields that range from biology, to cell physiology, through human health and disease. The relevance of the research to public health would go beyond the applications to peripheral arterial obstructive disease, since over 70 diseases are presently identified as angiogenesis-dependent, including ischemic heart disease, cancer, macular degeneration, rheumatoid arthritis, obesity, and neurodegenerative diseases. ? ? ?

Agency
National Institute of Health (NIH)
Institute
National Heart, Lung, and Blood Institute (NHLBI)
Type
Exploratory/Developmental Grants Phase II (R33)
Project #
7R33HL088286-03
Application #
7481165
Study Section
Special Emphasis Panel (ZHL1-CSR-K (S1))
Program Officer
Goldman, Stephen
Project Start
2006-09-27
Project End
2010-08-31
Budget Start
2008-09-16
Budget End
2010-08-31
Support Year
3
Fiscal Year
2008
Total Cost
$380,741
Indirect Cost
Name
University of Virginia
Department
Internal Medicine/Medicine
Type
Schools of Medicine
DUNS #
065391526
City
Charlottesville
State
VA
Country
United States
Zip Code
22904
Hazarika, Surovi; Farber, Charles R; Dokun, Ayotunde O et al. (2013) MicroRNA-93 controls perfusion recovery after hindlimb ischemia by modulating expression of multiple genes in the cell cycle pathway. Circulation 127:1818-28
Saqib, Amina; Prasad, Konkal-Matt R; Katwal, Arabindra B et al. (2011) Adeno-associated virus serotype 9-mediated overexpression of extracellular superoxide dismutase improves recovery from surgical hind-limb ischemia in BALB/c mice. J Vasc Surg 54:810-8
Hazarika, Surovi; Angelo, Michael; Li, Yongjun et al. (2008) Myocyte specific overexpression of myoglobin impairs angiogenesis after hind-limb ischemia. Arterioscler Thromb Vasc Biol 28:2144-50
Kappas, Nicholas C; Zeng, Gefei; Chappell, John C et al. (2008) The VEGF receptor Flt-1 spatially modulates Flk-1 signaling and blood vessel branching. J Cell Biol 181:847-58
Xie, Donghua; Hazarika, Surovi; Andrich, Amy J et al. (2008) High cholesterol feeding in C57/Blc6 mice alters expression within the VEGF receptor-ligand family in corporal tissue. J Sex Med 5:1137-48
Hazarika, Surovi; Dokun, Ayotunde O; Li, Yongjun et al. (2007) Impaired angiogenesis after hindlimb ischemia in type 2 diabetes mellitus: differential regulation of vascular endothelial growth factor receptor 1 and soluble vascular endothelial growth factor receptor 1. Circ Res 101:948-56